Medical Xpress on MSN9d
New 3D imaging technology could revolutionize medical diagnostics
In a paper featured on the cover of the Journal of Medical Imaging, Das explains how photon counting detectors along with ...
Medscape2d
Echocardiographic Contrast Agents: Safe and Efficacious
Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...
PharmiWeb6d
Global MRI Contrast Agents Market to Reach USD 1.23 Billion by 2029 at a 4.4% of CAGR
The MRI contrast agents market is expected to grow 1.3X from 2022 to 2029, reaching USD 1.23 Billion by 2029. Paramagnetic ...
Medscape7d
Advanced MRI Scanner Using Ultra-Low Magnetic Fields Promises Better Cancer Detection
New MRI scanning technology developed at Aberdeen University could improve cancer detection and reduce repeat surgeries by ...
pharmaphorum8d
Bayer reveals phase 3 data for improved MRI contrast agent
The company has reported the first phase 3 results in hand for gadoquatrane, which reduces the dose of gadolinium delivered ...
Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study
Sanochemia Pharmazeutika today announced positive headline results of the pivotal phase III study PROSTAPROGRESS on Ferumoxtran (EudraCT 2018-004310-18), performed by SPL Medical B.V. (Nijmegen, The ...
Bracco and Zereau Join Forces for Innovative Research Program Aimed at Improving Sustainability in Medical Imaging
Bracco Imaging SpA, a world leader in diagnostic imaging and Zereau BV, a provider of unique water technology for the ...
Morningstar9d
Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study
Ferumoxtran is an MRI Contrast Agent that may be used to detect lymph node metastases as small as 2 mm in prostate cancer patients. Sanochemia has secured exclusive global commercialization rights ...